Qingfeng Zeng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Qingfeng Zeng has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Jianping Luo
Department of Cardiology, Ganzhou Hospital‐Nanfang Hospital Southern Medical University (Ganzhou People's Hospital) Ganzhou Jiangxi China
3 shared publications - Xianghui Zeng
Department of Cardiology Ganzhou Hospital of Traditional Chinese Medicine Ganzhou Jiangxi China
3 shared publications - Chunqing Xiao
Department of Cardiology, Ganzhou Hospital‐Nanfang Hospital Southern Medical University (Ganzhou People's Hospital) Ganzhou Jiangxi China
2 shared publications Hengqing Zhu
Department of Cardiology, Ganzhou Hospital of Guangdong Provincial People's Hospital Ganzhou Municipal Hospital Ganzhou Jiangxi China
2 shared publications- Gang Cao
Department of Cardiology, Guangdong Provincial People's Hospital Ganzhou Hospital, Ganzhou Municipal Hospital, Ganzhou, China
1 shared publication - Guosheng Liu
Ganzhou Hospital of Traditional Chinese Medicine, Ganzhou, Jiangxi, China
1 shared publication
Latest Publications
- Open Access
- 9 July 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (7) , e70400
The Association Between Bending Photoplethysmography Waveform Area Index and Congestive Heart Failure
Aims: Congestive heart failure (CHF) is closely associated with a decrease in cardiac output, and photoplethysmography (PPG) parameters can experimentally assess cardiac output. It is unclear whether there is an association between the change of bending photoplethysmography waveform area index (BPWAI) due to postural changes and CHF. Methods: We enrolled patients with suspected CHF. Patients completed physical examination, echocardiography, and pro‐brain natriuretic peptide (NT‐proBNP) test during their visit, and finger‐end PPG waveform area was measured in the sitting and bending positions using PPG. We then used logistic regression to analyze the association between BPWAI and CHF, and the receiver operating characteristic (ROC) curve and area under the curve (AUC) were used to assess the event risk association strength. Results: A total of 523 patients with suspected CHF were included in this study, of whom 291 (55.6%) had a final diagnosis of CHF. The association between BPWAI and CHF decreased 0.45‐fold for per 1 standard deviation increase in BPWAI (OR: 0.55 [95% CI, 0.44−0.68]). The AUC for BPWAI associated with CHF was 0.736 (95% CI, 0.689−0.782), with a corresponding sensitivity of 67.4% and specificity of 71.5%, and a cut‐off value of 0.85 for the diagnosis of CHF. Conclusion: When patients bend over, their PPG waveform area decreases, which is closely associated with patients with CHF. BPWAI is significantly associated with CHF and may serve as a potential associated indicator for CHF.
- 9 July 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (7) , e70400
Open AccessThe Association Between Bending Photoplethysmography Waveform Area Index and Congestive Heart Failure
Aims: Congestive heart failure (CHF) is closely associated with a decrease in cardiac output, and photoplethysmography (PPG) parameters can experimentally assess cardiac output. It is unclear whether there is an association between the change of bending photoplethysmography waveform area index (BPWAI) due to postural changes and CHF. Methods: We enrolled patients with suspected CHF. Patients completed physical examination, echocardiography, and pro‐brain natriuretic peptide (NT‐proBNP) test during their visit, and finger‐end PPG waveform area was measured in the sitting and bending positions using PPG. We then used logistic regression to analyze the association between BPWAI and CHF, and the receiver operating characteristic (ROC) curve and area under the curve (AUC) were used to assess the event risk association strength. Results: A total of 523 patients with suspected CHF were included in this study, of whom 291 (55.6%) had a final diagnosis of CHF. The association between BPWAI and CHF decreased 0.45‐fold for per 1 standard deviation increase in BPWAI (OR: 0.55 [95% CI, 0.44−0.68]). The AUC for BPWAI associated with CHF was 0.736 (95% CI, 0.689−0.782), with a corresponding sensitivity of 67.4% and specificity of 71.5%, and a cut‐off value of 0.85 for the diagnosis of CHF. Conclusion: When patients bend over, their PPG waveform area decreases, which is closely associated with patients with CHF. BPWAI is significantly associated with CHF and may serve as a potential associated indicator for CHF.
- Open Access
- 13 June 2025
- Published by BMJ in BMJ Nutrition, Prevention & Health
- Vol. 8 (1) , 275-282
Association between dietary index for gut microbiota and hypertension: a large cross-sectional study from NHANES
Background: Gut microbiota is strongly associated with hypertension. The Dietary Index of Gut Microbiota (DI-GM) is a newly proposed indicator of the diversity of gut microbiota in the diet. However, the relationship between DI-GM and hypertension is unclear. Methods: Data for this study were obtained from the National Health and Nutrition Examination Survey (2007–2020). Dietary data were used to calculate DI-GM and grouped into three tertile groups. Survey logistic regression and restricted cubic spline (RCS) were used to analyse the association between DI-GM and hypertension. Results: A total of 20 804 participants (age ≥20 years) were enrolled in the study. After adjusting for all covariates, the ORs for hypertension in the medium DI-GM group (second quartile, 4–5) and high DI-GM group (third quartile, >5) were 0.94 (95% CI: 0.83 to 1.06) and 0.87 (95% CI: 0.76 to 0.99) compared with the low DI-GM group (first quartile, <4). Additionally, results from the RCS analysis indicated a linear association between DI-GM and hypertension (p value for non-linearity=0.57). Conclusion: Our findings suggest that higher DI-GM dietary patterns are associated with a lower prevalence of hypertension in a representative sample of US adults. These results suggest that dietary patterns characterised by a higher DI-GM may represent a potential strategy for the prevention of hypertension.
- 13 June 2025
- Published by BMJ in BMJ Nutrition, Prevention & Health
- Vol. 8 (1) , 275-282
Open AccessAssociation between dietary index for gut microbiota and hypertension: a large cross-sectional study from NHANES
Background: Gut microbiota is strongly associated with hypertension. The Dietary Index of Gut Microbiota (DI-GM) is a newly proposed indicator of the diversity of gut microbiota in the diet. However, the relationship between DI-GM and hypertension is unclear. Methods: Data for this study were obtained from the National Health and Nutrition Examination Survey (2007–2020). Dietary data were used to calculate DI-GM and grouped into three tertile groups. Survey logistic regression and restricted cubic spline (RCS) were used to analyse the association between DI-GM and hypertension. Results: A total of 20 804 participants (age ≥20 years) were enrolled in the study. After adjusting for all covariates, the ORs for hypertension in the medium DI-GM group (second quartile, 4–5) and high DI-GM group (third quartile, >5) were 0.94 (95% CI: 0.83 to 1.06) and 0.87 (95% CI: 0.76 to 0.99) compared with the low DI-GM group (first quartile, <4). Additionally, results from the RCS analysis indicated a linear association between DI-GM and hypertension (p value for non-linearity=0.57). Conclusion: Our findings suggest that higher DI-GM dietary patterns are associated with a lower prevalence of hypertension in a representative sample of US adults. These results suggest that dietary patterns characterised by a higher DI-GM may represent a potential strategy for the prevention of hypertension.
- Top Cited Papers
- 1 March 2025
- Published by Wolters Kluwer Health in Hypertension
- Vol. 82 (3) , 498-508
Trends in Obesity Prevalence Among Adults With Hypertension in the United States, 2001 to 2023
BACKGROUND: Obesity is a factor contributing to the occurrence of hypertension and a risk factor for adverse outcomes in populations with hypertension. The changes in the prevalence of obesity in populations with hypertension remain unclear. Investigating the changes in the prevalence of obesity in populations with hypertension can provide information for the treatment and management of hypertension. METHODS: The clinical data from adults aged ≥20 years with hypertension were extracted from the National Health and Nutrition Examination Survey 2001 to 2023. The primary outcome was the prevalence of obesity (body mass index≥30 kg/m 2 ). The trend in the prevalence of obesity among American adults with hypertension was evaluated via a trend test. RESULTS: The age-standardized prevalence of obesity among populations with hypertension in America increased from 39.6% in 2001 to 55.4% in 2023 ( P for trendP for trendP for trend2 ≤body mass index2 ) and grade III obesity (body mass index≥40 kg/m 2 ) increased significantly in both sexes, the prevalence of grade I obesity (30 kg/m 2 ≤body mass index2 ) increased significantly only in men (23.2%–30.0%; P for trend=0.003) and did not significantly change in women (22.2%–21.7%; P for trend=0.135). CONCLUSIONS: The prevalence of obesity among American adults with hypertension increased from 2001 to 2023. In men, the prevalence of grades I, II, and III obesity increased. Among women, the prevalence of only grades II and III obesity increased.
- 1 March 2025
- Published by Wolters Kluwer Health in Hypertension
- Vol. 82 (3) , 498-508
Top Cited PapersTrends in Obesity Prevalence Among Adults With Hypertension in the United States, 2001 to 2023
BACKGROUND: Obesity is a factor contributing to the occurrence of hypertension and a risk factor for adverse outcomes in populations with hypertension. The changes in the prevalence of obesity in populations with hypertension remain unclear. Investigating the changes in the prevalence of obesity in populations with hypertension can provide information for the treatment and management of hypertension. METHODS: The clinical data from adults aged ≥20 years with hypertension were extracted from the National Health and Nutrition Examination Survey 2001 to 2023. The primary outcome was the prevalence of obesity (body mass index≥30 kg/m 2 ). The trend in the prevalence of obesity among American adults with hypertension was evaluated via a trend test. RESULTS: The age-standardized prevalence of obesity among populations with hypertension in America increased from 39.6% in 2001 to 55.4% in 2023 ( P for trendP for trendP for trend2 ≤body mass index2 ) and grade III obesity (body mass index≥40 kg/m 2 ) increased significantly in both sexes, the prevalence of grade I obesity (30 kg/m 2 ≤body mass index2 ) increased significantly only in men (23.2%–30.0%; P for trend=0.003) and did not significantly change in women (22.2%–21.7%; P for trend=0.135). CONCLUSIONS: The prevalence of obesity among American adults with hypertension increased from 2001 to 2023. In men, the prevalence of grades I, II, and III obesity increased. Among women, the prevalence of only grades II and III obesity increased.
- 1 October 2023
- Published by Wolters Kluwer Health in Hypertension
- Vol. 80 (10) , 2149-2158
Prevalence of Chronic Kidney Disease Among US Adults With Hypertension, 1999 to 2018
BACKGROUND: Hypertension is a major cause of end-stage renal disease. Assessing temporal trends in the prevalence of chronic kidney disease (CKD) in hypertension could provide information for public health policies and plans. METHODS: From the National Health and Nutrition Examination Survey from 1999 to 2018, a probability sample of adults aged ≥20 years was collected. The primary outcomes were classified according to the estimated glomerular filtration rate and urinary albumin. Trend tests were performed to assess age-standardized prevalence trends of CKD, albuminuria, and macroalbuminuria in US adults with hypertension. RESULTS: A total of 23 120 US adults with hypertension were included in this study. The prevalence of any CKD, albuminuria, or macroalbuminuria in hypertension remained relatively stable. However, the age-standardized prevalence of stage 1 CKD in hypertension increased from 4.9% in 2003 to 2006 to 7.0% in 2015 to 2018 ( P =0.0077 for trend). The age-standardized prevalence of stage 3b CKD in hypertension decreased from 2.9% in 2011 to 2014 to 2.1% in 2015 to 2018 ( P =0.0350 for trend). A similar trend was observed for the age-standardized prevalence of stages 3 to 5 CKD in hypertension, which declined from 10.9% in 2011 to 2014 to 8.9% in 2015 to 2018 ( P =0.0160 for trend). CONCLUSIONS: Among US adults with hypertension, the prevalence of any CKD, albuminuria, and macroalbuminuria remained relatively stable from 1999 to 2018, whereas the hypertensive population showed an increasing trend in stage 1 CKD from 2003 to 2006 to 2015 to 2018 and a decreasing trend in the prevalence of stages 3 to 5 and 3b CKD from 2011 to 2014 to 2015 to 2018.
- 1 October 2023
- Published by Wolters Kluwer Health in Hypertension
- Vol. 80 (10) , 2149-2158
Prevalence of Chronic Kidney Disease Among US Adults With Hypertension, 1999 to 2018
BACKGROUND: Hypertension is a major cause of end-stage renal disease. Assessing temporal trends in the prevalence of chronic kidney disease (CKD) in hypertension could provide information for public health policies and plans. METHODS: From the National Health and Nutrition Examination Survey from 1999 to 2018, a probability sample of adults aged ≥20 years was collected. The primary outcomes were classified according to the estimated glomerular filtration rate and urinary albumin. Trend tests were performed to assess age-standardized prevalence trends of CKD, albuminuria, and macroalbuminuria in US adults with hypertension. RESULTS: A total of 23 120 US adults with hypertension were included in this study. The prevalence of any CKD, albuminuria, or macroalbuminuria in hypertension remained relatively stable. However, the age-standardized prevalence of stage 1 CKD in hypertension increased from 4.9% in 2003 to 2006 to 7.0% in 2015 to 2018 ( P =0.0077 for trend). The age-standardized prevalence of stage 3b CKD in hypertension decreased from 2.9% in 2011 to 2014 to 2.1% in 2015 to 2018 ( P =0.0350 for trend). A similar trend was observed for the age-standardized prevalence of stages 3 to 5 CKD in hypertension, which declined from 10.9% in 2011 to 2014 to 8.9% in 2015 to 2018 ( P =0.0160 for trend). CONCLUSIONS: Among US adults with hypertension, the prevalence of any CKD, albuminuria, and macroalbuminuria remained relatively stable from 1999 to 2018, whereas the hypertensive population showed an increasing trend in stage 1 CKD from 2003 to 2006 to 2015 to 2018 and a decreasing trend in the prevalence of stages 3 to 5 and 3b CKD from 2011 to 2014 to 2015 to 2018.